Related Experiment Video
Updated: Aug 7, 2026
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Hepatic resection for malignant melanoma
Introduction:
Patients with metastatic melanoma have a poor prognosis with a median survival of approximately 6 months. There is a paucity of data regarding the natural history of the disease in the small subset of patients who are suitable for hepatic resection for metastatic disease confined to the liver.
Patients And Methods:
Five patients were identified from a prospectively collected database of over 1000 liver resections performed in Basingstoke between 1986 and 2004. Clinical details and survival were analysed.
Results:
Two patients died within 12 months of resection from extrahepatic disease. The other three patients are alive and disease-free at 76, 92 and 147 months, respectively.
Discussion:
In carefully selected cases, hepatic resection for metastatic melanoma to the liver can result in long-term survival. Criteria for selection of patients as suitable for resection remain unclear.
